SCHEMBL186132

SCHEMBL186132

O=C(O)c1c(F)ccc(O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELL P14151 2/20 0.46
SELP P16109 2/20 0.46
CA1 P00915 6/20 0.44
CA2 P00918 6/20 0.44
CA12 O43570 4/20 0.44
CA7 P43166 4/20 0.44
CA9 Q16790 4/20 0.44
CA14 Q9ULX7 4/20 0.44
ALB P02768 2/20 0.42
KDM4E B2RXH2 4/20 0.41
LMNA P02545 3/20 0.41
HSD17B10 Q99714 3/20 0.41
DPP4 P27487 2/20 0.40
MAPT P10636 2/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 1/20 0.39
CA3 P07451 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21262024 0.86 ALB (0.50) SELLSELPCA1CA2CA12
SCHEMBL31197230 0.82 HSD17B1 (0.49) CA1CA2CA12CA7CA9
SCHEMBL27433691 0.82 HSD17B1 (0.49) CA1CA2CA12CA7CA9
SCHEMBL30405434 0.80 CA1 (0.59) SELLSELPCA1CA2CA12
SCHEMBL973491 0.80 CA1 (0.59) SELLSELPCA1CA2CA12
SCHEMBL22133774 0.80 THRB (0.46) SELLSELPCA9KDM4EHSD17B10
SCHEMBL30048528 0.80 CES2 (0.50) CA1CA2CA12CA7CA9
SCHEMBL3309453 0.80 CES2 (0.50) CA1CA2CA12CA7CA9
SCHEMBL5002680 0.78 ALDH1A1 (0.44) CA1CA2CA12CA7CA9
SCHEMBL27759044 0.78 CA1 (0.44) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663626-A1 IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Bio Genuine (Shanghai) Biotech Co., Ltd (CN) 2025-12-17 EP disclosed
EP-4612134-A1 DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 EP disclosed
WO-2024165071-A1 IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 上海葆正医药科技有限公司 2024-08-15 WO disclosed
WO-2024095005-A1 DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 WO disclosed
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-115232144-A Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-10-25 CN disclosed
WO-2021117710-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND AND ELECTRONIC DEVICE 出光興産株式会社 2021-06-17 WO disclosed
WO-2020235558-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND, AND ELECTRONIC APPLIANCE 出光興産株式会社 (JP) 2020-11-26 WO disclosed
WO-2020122118-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE 出光興産株式会社 2020-06-18 WO disclosed
US-8778510-B2 Pyrromethene-boron complex compounds and organic electroluminescent elements using same IDEMITSU KOSAN CO., LTD. (JP) 2014-07-15 US disclosed
EP-2402351-B1 PYRROMETHENE-BORON COMPLEX COMPOUNDS AND ORGANIC ELECTRO- LUMINESCENT ELEMENTS USING SAME IDEMITSU KOSAN CO (JP) 2013-10-09 EP disclosed
US-20120037890-A1 PYRROMETHENE-BORON COMPLEX COMPOUNDS AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME MITSUI CHEMICALS, INC. 2012-02-16 US disclosed
EP-2402351-A1 PYRROMETHENE-BORON COMPLEX COMPOUNDS AND ORGANIC ELECTRO- LUMINESCENT ELEMENTS USING SAME Idemitsu Kosan Co., Ltd. (JP) 2012-01-04 EP disclosed
US-7501516-B2 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2009-03-10 US disclosed
EP-1409481-B1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-10-04 EP disclosed
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2005-01-13 US disclosed
EP-1409481-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS Astrazeneca AB (SE) 2004-04-21 EP disclosed
WO-2003047582-A1 QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS ASTRAZENECA AB (SE) 2003-06-12 WO disclosed
WO-2003008409-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120037890-A1 PYRROMETHENE-BORON COMPLEX COMPOUNDS AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME LEF1, ZRANB2, AFF1 SELL 4113/4885SELP 1586/4885CA1 2374/4885
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ABL1, FLT3, JAK2 SELL 2007/4885SELP 3021/4885CA1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.